HER-2/Neu Alterations in Non-Small Cell Lung Cancer: A Comprehensive Evaluation by Real Time Reverse Transcription-PCR, Fluorescence in Situ Hybridization, and Immunohistochemistry

Clinical Cancer Research

Volumn 9, Issue 10, 2003, Pages 3645-3652

  Pellegrini, Caterina ^a   Falleni, Monica ^a   Marchetti, Antonio ^c   Cassani, Barbara ^a   Miozzo, Monica ^a   Buttitta, Fiamma ^c   Roncalli, Massimo ^a   Coggi, Guido ^a,b   Bosari, Silvano ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Interuniv Center of Cancer Research   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATION; ONCOGENE NEU; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0141456467     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Yokota, J., Terada, M., and Toyoshima, K. Amplification of cerb-B2 oncogene in human adenocarcinomas in vivo. Lancet, 1: 765–767, 1986.
2. Slamon, D. J., Clark, J. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. Human breast cancer: correlation of relapse and survival with amplification with the HER2/neu oncogene. Science (Wash. DC), 235: 177–182, 1987.
3. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. O., Keith, D. E., Lewis, W. J., Sturt, S. O., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER/2 proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707–712, 1989.
4. Tal, M., Wetzler, M., and Josefberg, Z. Sporadic amplification of HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res., 48: 1517–1520, 1998.
5. Wright, C., Angus, B., Nicholson, S., Sinsbury, J. R. C., Cairns, J., Gullik, W., Kelly, P., Harris, A., and Horme, W. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res., 49: 2087–2090, 1989.
6. Stal, O., Sullivan, S., Wingren, S., Skoog, L., Rutqvist, L. E., Carstensen, J. M., and Nordenskjold, B. C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur. J. Cancer, 31: 2185–2190, 1995.
7. Muss, H. B., Thor, A. D., Berry, D. A., Donald, A., Kute, T., Liu, E. T., Koener, F., Cirrincione, C. T., Udman, DR., Wood, W. C., Barcos, M., and Henderson, I. C. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med., 330: 1260–1266, 1994.
8. Yu, D., Wang, S-S., Dulski, K. M., Tasi, C-M., Nicolson, G. L., and Hung, M-C. C-erbB2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res., 54: 3260–3266, 1994.
9. Wright, C., Nicholson, S., Angus, B., Sainsbury, J. R., Farndon, J., Cairns, J., Harris, A. L., and Horne, C. H. Relationship between c-erbB2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer, 65: 118–121, 1992.
10. Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D’Antonio, A., Bianco, A. R., and De Placido, S. C-erb-B2 overexpression decreases the benefit of adjuvant tamoxifen in early stage breast cancer without axillary lymphnode metastasis. J. Clin. Oncol., 14: 2702–2708, 1996.
11. Baselga, J., Norton, L., Albanell, J., Kim, Y-M., and Mendelsohn, J. Recombinant humanized anti-HER-2 antibody (Herceptin) enhances the antitumor activity of Paclitaxel and Doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 58: 2825– 2831, 1998.
12. Mitchell, M. S., and Press, M. F. The role of immunohistochemistry and fluorescent in situ hybridisation for HER-2/neu in assessing the prognosis of breast cancer. Semin. Oncol., 26 (Suppl. 12): 108–116, 1999.
13. Noguchi, M., Murakami, M., Bennett, W., Lupu, R., Hiu, F., Harris, C. C., and Gerwin, B. I. Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells. Cancer Res., 53: 2035–2043, 1993.
14. Kern, J. A., Slebos, R. J. C., Top, B., Rodenhuis, S., Lager, D., Robinson, R. A., Weiner, D., and Schwartz, D. A. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J. Clin. Investig., 93: 516– 520, 1994.
15. Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Di Fiore, P. P., and Kraus, M. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene, 10: 1813–1821, 1995.
16. Pietras, R. J., Fendly, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., and Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829–1838, 1994.
17. Tan, M., Yao, J., and Yu, D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transforming abilities. Cancer Res., 57: 1199– 1205, 1997.
18. Sliwkowski, M. X., Lofgren, J. A., Lewis, G. D., Hotaling, T. E., Fendly, B. M., and Fox, J. A. Non clinical studies addressing the mechanism of action of Trastuzumab (Herceptin). Semin. Oncol., 26 (Suppl. 12): 60–70, 1999.
19. Weiner, L. M. Monoclonal antibody therapy of cancer. Semin. Oncol., 26 (Suppl. 1): 43–51, 1999.
20. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eierman, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against Her2/neu for metastatic breast cancer that overexpresses Her2/neu. N. Eng. J. Med., 344: 783–792, 2001.
21. Hirsch, F. R., Franklin, W. A., Veve, R., Varella-Garcia, M., and Bunn, P. A. Her2/neu expression in malignant lung tumors. Semin. Oncol., 29: 51–58, 2002.
22. Hirsch, F. R., Franklin, W. A., and Bunn, P. A., Jr. What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer? Lung Cancer, 36: 263–264, 2002.
23. Kern, J. A., Schwartz, D. A., Nordberg, J. E., Weiner, D. B., Greene, M. I., Torney, L., and Robinson, R. A. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 50: 5184–5191, 1990.
24. Weiner, D. B., Nordberg, J., Robinson, R., Nowell, P. C., Gazdar, A., Greene, M. I., Williams, W. V., Cohen, J. A., and Kern, J. A. Expression of the neu gene-encoded protein (p185neu) in human non small cell carcinomas of the lung. Cancer Res., 50: 421–425, 1990.
25. Tateishi, M., Ishida, T., Mitsudomi, T., Kaneko, S., and Sugimachi, K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur. J. Cancer, 27: 1372–1375, 1991.
26. Tateishi, M., Ishida, T., Kohdono, S., Hamatake, M., Fukuyama, Y., and Sigimachi, K. Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg. Oncol., 3: 109–113, 1994.
27. Shi, D., Gongping, H., Cao, S., Pan, W., Zhang, H. Z., Yu, D., and Hung, M-C. Overexpression of the c-erb-B2/neu-encoded p185 protein in primary lung cancer. Mol. Carcinog., 5: 213–218, 1992.
28. Volm, M., Efferth, T., and Mattern, J. Oncoprotein (c-myc, cerbB1, c-erbB2, c-fos) and suppressor gene products (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res., 12: 11–20, 1992.
29. Bongiorno, P. F., White, R. I., Lesser, E. J., Moore, J. H., Orringer, M. B., and Beer, D. G. Alterations of K-ras, p53 and c-erbB-2/neu in human lung adenocarcinomas. J. Thorac. Cardiovasc. Surg., 107: 590– 595, 1994.
30. Harpole, D. H., Herndone, J. E., Wolfe, W. G., Iglehart, J. D., and Marks, J. R. A. prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res., 55: 51–56, 1995.
31. Tsai, C-M., Chang, K-T., Wu, L-H., Chen, J. Y., Gazdar, A. F., Mitsudomi, T., Chen, M. H., and Perng, R. P. Correlations between intrinsic chemoresistence and HER2/neu gene expression, p53 mutations, and cell proliferation characteristics in non small cell lung cancer cell lines. Cancer Res., 56: 206–209, 1996.
32. Pfeiffer, P., Clausen, P. P., Andersen, K., and Rose, C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated nonsmall-cell-lung cancer: an immunohistochemical study on cryosections. Br. J. Cancer, 74: 86–91, 1996.
33. Pastorino, U., Andreola, S., Tagliabue, E., Pezzella, F., Incarbone, M., Sozzi, G., Buyse, M., Menard, S., Pierotti, M., and Rilke, F. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J. Clin. Oncol., 15: 2858–2865, 1997.
34. Hirsh, F. R., Varella-Garcia, M., Franklin, W. A., Veve, R., Chen, L., Helfrich, B., Zeng, C., Baron, A., and Bunn, P. A., Jr. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer, 86: 1449–1456, 2002.
35. Cline, M. J., and Battifora, H. Abnormalities of proto-oncogenes in non small cell lung cancer. Cancer (Phila.), 60: 2669–2674, 1987.
36. Schneider, P. M., Hung, M-C., Chiocca, S. M., Manning, J., Zhao, X., Fang, K., and Roth, J. A. Differential expression of the c-erbB2 gene in human small cell and non small cell lung cancer. Cancer Res., 50: 5184–5191, 1989.
37. Brabender, J., Danenberg, K. D., Metzger, R., Schneider, P. M., Park, J., Salonga, D., Holscher, A. H., and Danenberg, P. V. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res., 7: 1850–1855, 2001.
38. Zinner, R. G., Kim, J., and Herbst, R. S. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer, 37: 17–27, 2002.
39. Marchetti, A., Pellegrini, C., Buttitta, F., Falleni, M., Romagnoli, S., Felicioni, L., Barassi, F., Salvatore, S., Chella, A., Angeletti, A. C., Roncalli, M., Coggi, G., and Bosari, S. Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab. Investig., 82: 729–736, 2002.
40. Nuciforo, P. G., Pellegrini, C., Fasani, R., Maggioni, M., Coggi, G., Parafioriti, A., and Bosari, S. Molecular and immunohistochemical analysis of HER2/neu in synovial sarcoma. Hum. Pathol., 34: 639–645, 2003.
41. Kraus, M. H., Popescu, N. C., Amsbaugh, S. C., and King, C. R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J., 6: 605–610, 1987.
42. Mass, R., Sanders, C., and Kasian, C. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridisation (FISH) in the Herceptin pivotal trials. Proc. Am. Soc. Clin. Oncol., 19: 74a, 2000.
43. Lebeau, A., Deimling, D., Kaltz, C., Sendelhofert, A., Iff, A., Luthardt, B., Untch, M., and Lohrs, U. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridisation. J. Clin. Oncol., 19: 354–363, 2001.
44. Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., and Schnitt, S. J. Specificity of Hercept Test in determining the Her-2/ neu status of breast cancers using the United States Food and Drug Administration approved scoring system. J. Clin. Oncol., 17: 1983– 1987, 1999.
45. Pauletti, G., Godolphin, W., Press, M. F., and Slamon, D. J. Detection and quantitation of HER-2/neu gene aplification in huan reast cancer archival atherial using fluorescence in situ hybridization. Oncogene, 13: 63–72, 1996.
46. Bartlett, J. M. S., Going, J. J., Mallon, E. A., Watters, A. D., Reeves, J. R., Stanton, P., Richmond, J., Donald, B., Ferrier, R., and Cooke, T. J. Evaluating HER2 amplification and overexpression in breast cancer. J. Pathol., 195: 422–428, 2001.
47. Bunn, P. A., Helfrich, B., Soriano, A. F., Franklin, W. A., Varella-Garcia, M., Chan, D., Hirsch, F. R., Baron, A., Zeng, C., and Chan, D. C. Expression of Her2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin. Cancer Res., 7: 3239–3250, 2001.
48. Shiraishi, M., Noguchi, M., Shimosato, Y., and Sekiya, T. Amplification of protooncogenes in surgical specimens of human lung carcinomas. Cancer Res., 49: 6474–6479, 1989.
49. Kern, J. A., Robinson, R. A., Gazdar, A., Torney, L., and Weiner, D. B. Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines. Am. J. Respir. Cell Mol. Biol., 6: 359–363, 1992.
50. Heinmoller, P., Gross, C., Schimdtgen, C., et al. HER2 status in non-small cell lung cancer (NSCLC): results from the patient screening for enrollment to a phase 2 study of Herceptin. Proc. Eur. Cancer Con., 11: S50, 2001.
51. Liu, C., and Tsao, M. S. In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small cell lung carcinomas. Am. J. Pathol., 142: 1155–1162, 1993.
52. Gibson, U. E. M., Heid, C. A., and Williams, P. M. A novel method for real time RT-PCR. Genome Res., 6: 995–1001, 1996.
53. Bieche, I., Onody, P., Laurendeau, I., Olivi, M., Vidaud, D., Lidereau, R., and Vidaud, M. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin. Chem., 45: 1148–1156, 1999.